Table 2 EC ₅₀ of the ligustrazine derivatives for protecting damaged PC12 cells

L1

−20.01

−14.71

5.47

−8.63

−15.83

150

L2

18.94

18.52

12.48

2.80

−10.53

74

L3

38.69

14.19

12.04

−0.57

−7.52

64

L4

8.91

9.20

11.86

4.92

1.61

77

L5

3.28

4.31

13.63

9.98

1.79

78

L6

8.68

30.75

9.73

9.06

3.07

62

L7

7.63

9.29

17.83

11.37

0.51

71

L8

3.00

7.39

54.75

35.16

0.06

46

L9

6.05

7.50

−3.24

−3.46

−8.38

102

L10

47.63

38.14

36.80

35.01

21.74

25

L11

46.64

43.34

33.42

24.46

22.52

27

L12

26.42

19.94

13.47

13.29

10.75

53

L13

3.35

4.89

40.02

14.72

−6.53

64

L14

−13.55

9.81

16.80

1.94

−11.97

98.

L15

−1.40

17.23

25.56

10.54

−19.67

92

L16

−8.69

−2.40

13.41

−1.28

−1.36

103

L17

11.58

28.77

39.01

10.12

−20.20

60

L18

0.05

0.31

8.58

−0.51

−8.65

101

L19

17.95

19.80

22.80

24.53

24.06

44

L20

13.94

19.41

25.05

28.12

34.42

40

L21

27.59

28.12

29.80

25.51

24.52

36

TMP

14.71

12.11

11.76

10.60

9.44

65